You are here: Industry Insights > ADC

News List

ADCendo secures loan to advance ADCs for cancer treatment pharmaceutical-technology
September 03, 2019
ADCendo has secured a loan amount to advance its novel antibody-drug conjugates (ADCs) that are being developed to treat cancers.
ADC Therapeutics, Freenome Enter Biomarker Development Collaboration contractpharma
August 29, 2019
ADC Therapeutics to employ Freenome's multiomics platform to identify biomarkers that correlate with clinical response to ADCT-402.
ADC Therapeutics, SOPHiA GENETICS Partner for Biomarker Discovery contractpharma
August 08, 2019
Pivotal Phase II trial to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) in DLBCL.
Abzena Completes ADC Tech Transfer contractpharma
July 24, 2019
Successful technical transfer of Synaffix GlycoConnect ADC Technology to enable use in client projects.
ADC Bio’s New State of the Art Cleanroom Competed by WHP contractpharma
July 16, 2019
The GMP facility has been designed to deliver next gen anticancer blockbuster ADC drugs for patients globally.
WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing En-CPhI.cn
June 24, 2019
WuXi Biologics development and manufacturing, announced that it planned to expand the new state-of-the-art integrated biologics conjugation solution center to include commercial manufacturing in Wuxi city, China.
Piramal Invests $10 million in Riverview Expansion contractpharma
June 24, 2019
Expands High Potency API Capability to serve the growing ADC market.
WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership en-cphi.cn
April 09, 2019
WuXi Biologics and NBE-Therapeutics (NBE) announced a comprehensive development and manufacturing partnership for NBE's first ADC lead product NBE-002 (anti-ROR1). NBE-002 is a best-in-class immune-stimulatory ADC (iADC) treatment...
Iksuda Therapeutics and Femtogenix Sign License Agreement pharmafocusasia
March 07, 2019
Iksuda Therapeutics (Iksuda), the next-generation Antibody Drug Conjugate (ADC) company, today announced it has signed a licensing agreement with Femtogenix Limited (FGX), the next-generation ADC payload company.
Oxford BioTherapeutics Receives IND Clearance for OBT076 americanpharmaceuticalreview
December 24, 2018
Oxford BioTherapeutics has received US Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for OBT076.....

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page